Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Hiberix
Generic Name
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DrugBank Accession Number
DB10990
Background

Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primarly immunization. The vaccine contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]), which is a high molecular weight polymer prepared from the Haemophilus influenzae type b strain 20,752. These are heat inactivated and purified.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Toxoid
Synonyms
  • Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine

Pharmacology

Indication

Indicated for active immunization in pediatric patients 15 months through 4 years of age as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Acetylsalicylic acid.
AdalimumabThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Altretamine.
Aminosalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Aminosalicylic acid.
AmsacrineThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Anakinra.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
HiberixInjection, powder, lyophilized, for solution10 ug/0.5mLIntramuscularGlaxoSmithKline Biologicals SA2009-08-242009-08-19US flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
HiberixHaemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Water (1 mL/1mL)KitIntramuscularGlaxoSmithKline Biologicals SA2015-12-21Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ACT-HIB 0,5ML IM/SC 1 FLK LIYOFILIZE ASI+1 ENJ. COZUCUHaemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg/0.5mL)Powder, for solutionIntramuscular; Subcutaneous2020-08-14Not applicableTurkey flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
C9R35M8XV6
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911072
RxNav
1300806

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingPreventionPneumococcal Infection / Vaccines, Pneumococcal1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionAcellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionAcellular Pertussis / Diphtheria / Tetanus2
3CompletedPreventionDiphtheria / Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin / Haemophilus Influenzae Type B / Tetanus / Viral Hepatitis B / Whole Cell Pertussis2
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type b (Hib) / Pertussis / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Tetanus / Viral Hepatitis B / Whole Cell Pertussis5
3CompletedPreventionHaemophilus Influenzae Type B1
3CompletedPreventionHaemophilus Influenzae Type b (Hib) Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionIntramuscular; Subcutaneous
Injection, powder, for solutionIntramuscular
Injection, powder, lyophilized, for solutionIntramuscular10 ug/0.5mL
KitIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:04 / Updated on June 12, 2020 16:53